PriceSensitive

Nanoveu (ASX:NVU) shares soar on positive results for anti-viral smartphone case

Technology
ASX:NVU      MCAP $7.577M
05 May 2020 13:00 (AEST)

Mobile screen protector company, Nanoveu (NVU) has received positive testing results for its anti-viral smartphone case and screen protector.

Smartphones are germ magnets, and bacteria that latch on can potentially live on your phone’s screen for days.

An independent analysis of Nanoveu’s anti-viral smartphone screen and case was undertaken by the Department of Microbiology and Immunology at the Yong Loo Lin School of Medicine in Singapore.

The antimicrobial technology proved to be effective against a coronavirus strain found in mice, known as MHV-A59. During testing, 90 per cent of the coronavirus particles placed on the smartphone screen and cover were eliminated within 10 minutes.

Nanoveu is aiming to have both anti-viral products available by the third quarter of 2020.

“The Nanoveu technology is poised to revolutionise safety for all mobile phone users and the results from the National University of Singapore further validates our inherent value proposition as a timely product in today’s evolving world impacted by the COVID-19 Pandemic,” CEO Alfred Chong said.

“We are thrilled to be able to demonstrate, via a highly reputable research institute, that Nanoveu’s phone protection technology can reduce active coronavirus particles by a factor of 10 in just 10 minutes,” he added.

Antiviral case prototype. Sourced from Nanoveu.

Types of coronavirus

There are four genera of coronavirus; the Alpha, Beta, Delta, and Gamma families.

The MHV-A59 strand is a type of Betacoronavirus. Betacoronaviruses are single-stranded RNA viruses, which come from animals and are typically associated with respiratory illness. For example, SARS, MERS, and COVID-19 are all forms of betacoronavirus.

What’s next?

Additional testing is currently ongoing at a laboratory in the United States, and Nanoveu will update the market once it has these results.

The company is expecting to also test its technology against coronavirus OC43, which is a Betacoronavirus, and is a known cause of the common cold.

Nanoveu is up 237 per cent on the market this morning, selling shares for 15.5 cents each at 11:19 am AEST.

Related News